NEXI NexImmune, Inc. Net earnings per share growth this year

NexImmune, Inc. (NEXI) is optimizing costs by outsourcing substance production to third-party laboratories. The absence of current revenue makes the company dependent on clinical trial outcomes, while pricing power is limited by grants and patents. The annual EPS variation illustrates earnings per share dynamics, where the 0.00 indicator expresses the state of the metric, helping traders filter out market noise when analyzing business sustainability.

NexImmune (NEXI): Net earnings per share growth this year from 07/04/2022 to 08/04/2024

Analytical breakdowns and data insights for company NexImmune Corporation (NEXI)

- current quotes and average value forecast:

Market Chart NexImmune Corporation|NEXI - Price Target Chart

- market capitalization data:

Market Valuation NexImmune, Inc.|NEXI - Total Company Value

- company book value details:

Accounting Value per Share NexImmune|NEXI - Company Net Assets|Market Capitalization to Book Value Ratio neximmune.com|NEXI - Aggregate Company Assets

- debt and liquidity details:

- net income and valuation ratios data:

NEXI - Net Profit|Expected Net Profit NexImmune, Inc.|NEXI - Price to Earnings Ratio|Future Price to Earnings Multiple NexImmune, Inc.|NEXI - PEG Multiple|EV/EBITDA Multiple NexImmune, Inc.|NEXI - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months NexImmune|NEXI - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months neximmune.com|NEXI - Earnings per share growth in current year|Projected earnings per share growth rate for next year NexImmune, Inc.

- company sales and revenue statistics:

NEXI - Revenue and Sales Volume|Company Expected Sales Volume NexImmune, Inc.|NEXI - Market Cap to Revenue|Market Cap to Projected Revenue NexImmune|NEXI - Sales Growth YoY (TTM)

Summary company analysis:NEXI (NexImmune, Inc.)

This indicator captures the annual earnings per share (EPS) trend, allowing investors to promptly identify trend reversals and avoid capital losses during periods of stagnation. The current value of 0.00 serves as an objective measure of financial efficiency, eliminating market speculation. Analyzing comparable year-over-year EPS growth is critical for NexImmune, Inc. (NEXI), as it reflects the commercial success of scaling the AIM platform and the precision of the immune response in tumor treatment.

Key competitors